Related Experiment Video
Updated: Dec 9, 2025
Lung Tumor Cell Recruitment Assay
Published on: February 26, 2019
Prognostic values of various hematological variables as markers of systemic inflammation in metastatic lung cancer
Duygu Bayir1, Selcuk Seber1, Tarkan Yetisyigit1
1Department of Internal Medicine, Namik Kemal University Hospital, Tekirdag, Turkey.
Background:
Chronic state of inflammation is an important factor in advanced cancer which is used by tumor cells for maintaining survival and growth. Hematological parameters such as neutrophil/lymphocyte ratio (NLR), thrombocyte/lymphocyte ratio (TLR), and lymphocyte/monocyte ratio (LMR) are reliable indicators of systemic inflammation. We aimed to elucidate the effect of hematological parameters and clinical features of patients on the prognosis of advanced-stage non-small cell lung cancer (NSCLC).
Methods:
We included 102 Stage IV NSCLC patients who presented to the oncology clinic between 2010 and 2016. Pretreatment clinical parameters and NLR, TLR, and LMR were retrieved from the medical records. The cutoff values, calculated with receiver operating curve analysis, for NLR, LMR, and TLR were 2.5, 3, and 183, respectively. All patients were divided into two groups according to cutoff values and analyzed accordingly.
Results:
Median overall survival and progression-free survival were 10 and 6 months, respectively. In univariate analysis, high NLR, high TLR, and low LMR were found to be significantly associated with survival. Among clinical parameters having eastern cooperative oncology group performance score 0-1, older age (≥70 years) single metastatic disease was prognostic. In multivariate Cox regression analysis, only the number of metastatic lesions and LMR were found to be independent predictors for survival.
Conclusion:
Among hematological parameters, only LMR was found to be an independent predictor of survival in patients with advanced-stage NSCLC.
